Seyed-Mahmood Seyed-Khorrami | Cancer | Best Researcher Award

Assist. Prof. Dr. Seyed-Mahmood Seyed-Khorrami | Cancer | Best Researcher Award

Tarbiat Modares University | Iran

Seyed-Mahmood Seyed-Khorrami is a medical virologist with advanced academic training, holding a doctorate in medical virology from Tarbiat Modares University, a master’s degree in medical virology from Tehran University of Medical Sciences, and a bachelor’s degree in biology from Tabriz University. His professional experience spans diverse roles, including specialty expert at the Center for Disease Control and Prevention, laboratory technical officer and manager in research and development, consultant virologist in an HPV clinic, and active member of national COVID-19 diagnostic and research projects. He has also contributed as a teaching assistant in cell culture, virus propagation, and molecular techniques. His research interests focus on oncolytic viruses in cancer therapy, viral pathogenesis, emerging and re-emerging viral diseases, animal experiments, and nanotechnology-based vaccines and delivery systems. He possesses strong laboratory expertise in virus propagation, molecular diagnostics, cloning, flow cytometry, animal handling, and bioinformatics, alongside certifications in biosafety, GLP, and quality management. His publication record includes impactful contributions in international journals on cancer immunotherapy, COVID-19, viral epidemiology, and nanovaccine development, complemented by book authorship and conference presentations. He has served as a reviewer for multiple journals and has secured competitive grants for his research. Recognized for his scientific contributions, he demonstrates an outstanding blend of research skills, professional commitment, and leadership. In conclusion, his career reflects a dynamic integration of virology, translational research, and innovation with promising potential for impactful contributions to global health.

Profile: Google scholar

Featured Publications

Hongru Li | Brain Metastasis | Best Researcher Award

Dr. Hongru Li | Brain Metastasis | Best Researcher Award

Fuzhou University Affiliated Provincial Hospital | China

Dr. Hongru Li, MD/PhD, is a distinguished clinician-scientist and Chief Physician in the Department of Respiratory and Critical Care Medicine at Fujian Provincial Hospital, Fujian Medical University. With a career dedicated to advancing respiratory medicine and oncology, his expertise lies in lung cancer, metastasis mechanisms, and innovative therapeutic strategies. Over the years, he has combined clinical excellence with groundbreaking research, focusing on molecular pathways and targeted therapies. Dr. Li has published extensively in reputable journals, contributing to understanding brain and bone metastasis in non-small cell lung cancer. His leadership extends to supervising clinical innovation projects funded by national and provincial research grants. Recognized as an outstanding respiratory scholar, he has made notable contributions in translational medicine, bridging laboratory findings with patient care. His research on nanoliposomes, ceramide pathways, and genetic susceptibility in lung cancer exemplifies his commitment to improving treatment outcomes and patient survival in respiratory oncology.

Profile

ORCID

Education

Dr. Hongru Li’s academic foundation is firmly rooted in medicine and specialized respiratory science. He earned his Doctor of Medicine degree at Fujian Medical University, where he developed his core clinical knowledge and interest in pulmonary health. To deepen his expertise, he pursued postgraduate studies in respiratory medicine at Fujian Medical University, gaining hands-on exposure to advanced diagnostic and therapeutic approaches in pulmonary and critical care. His academic journey culminated with a PhD in Respiratory Medicine from Southern Medical University in Guangzhou, where he focused on molecular mechanisms of lung cancer progression and metastasis. His doctoral research provided a solid grounding in translational medicine, integrating clinical insights with cellular and molecular biology. This comprehensive educational background has enabled him to pursue a career balancing patient care with high-impact research, positioning him as a leader in respiratory medicine, oncology, and translational research with a strong focus on innovation and clinical application.

Experience

Dr. Hongru Li has accumulated extensive clinical and academic experience at Fujian Provincial Hospital, where he has advanced through progressive leadership roles in respiratory and critical care medicine. Starting as a resident doctor, he gained experience in managing complex respiratory cases, developing proficiency in critical care interventions. He then served as an attending doctor, where he refined his clinical judgment and mentored junior staff. His expertise led to his appointment as Associate Chief Physician, where he oversaw specialized clinical programs and research initiatives. Currently, as Chief Physician, Dr. Li leads the Department of Respiratory and Critical Care Medicine, managing advanced patient care, research collaborations, and clinical training. His responsibilities span from clinical decision-making to developing research projects funded by provincial and national agencies. With deep involvement in translational research, he bridges laboratory discoveries with real-world patient care, positioning him as both a skilled clinician and an innovative medical researcher.

Awards and Honors

Dr. Hongru Li has been recognized for his exceptional contributions to clinical medicine, research innovation, and academic excellence. Early in his career, he received the Excellent Graduate Award and Excellent Postgraduate Award from Fujian Medical University, reflecting his academic dedication and professional promise. His trajectory of excellence was further reinforced with the prestigious Outstanding Youth Respiratory Scholar Award for Clinical Innovation in China, acknowledging his groundbreaking research and leadership in respiratory medicine. These honors underscore his commitment to advancing lung cancer research, patient care, and translational medicine. His ability to secure competitive research funding and lead innovative studies further reflects his recognition as a trusted expert in his field. In addition, his patents and numerous peer-reviewed publications highlight the impact of his scientific contributions. These accolades collectively demonstrate not only his academic excellence but also his role as a leading physician-researcher shaping the future of respiratory and oncology medicine.

Research Focus

Dr. Hongru Li’s research centers on the molecular mechanisms driving lung cancer progression and metastasis, with particular emphasis on brain and bone metastases in non-small cell lung cancer. He explores signaling pathways, genetic susceptibility, and the role of lipids and ceramide metabolism in tumor development. His studies have investigated proteins such as livin, RPTOR, and ceramide synthase in regulating tumor proliferation, apoptosis, and metastatic spread. Through innovative approaches, including nanoliposome-based therapies, he seeks to inhibit cancer metastasis and improve treatment responses. He has also examined genetic polymorphisms and signaling cascades, such as the PI3K/AKT/mTOR and Wnt pathways, to understand cancer susceptibility and therapy resistance. His translational research aims to transform laboratory findings into clinical applications, offering new diagnostic biomarkers and therapeutic targets. Supported by national and provincial grants, his work significantly contributes to advancing precision medicine, improving survival, and developing novel treatment strategies for patients with lung cancer.

 

Publications

 

Title: KLF9 Inhibits Brain Metastasis of Non‐Small Cell Lung Cancer by Regulating Ceramide Synthase 1 Synthesis
Year: 2025

Title: Efficacy of Prophylactic Cranial Irradiation in Early to Mid-stage Small Cell Lung Cancer Patients in the Era of Magnetic Resonance Imaging
Year: 2024

Title: Development and validation of a nomogram model based on blood-based genomic mutation signature for predicting the risk of brain metastases in non-small cell lung cancer
Year: 2024

Title: Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic Klebsiella pneumoniae
Year: 2024

Title: Clinical application value of metagenome next-generation sequencing in pulmonary diffuse exudative lesions: a retrospective study
Year: 2024

Title: Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib
Year: 2024

Title: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding
Year: 2024

Conclusion

Dr. Hongru Li exemplifies the integration of clinical expertise and research innovation, dedicated to advancing respiratory and cancer medicine through groundbreaking studies, translational discoveries, and compassionate patient care.

Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Dr. Michela Simone | Boron Neutron Capture Therapy | Best Researcher Award

Commonwealth Scientific and Industrial Research Organisation | Australia

Dr. Michela Simone is a distinguished scientist with expertise spanning green chemistry, renewable energy, carbohydrate chemistry, glycobiology, ionic liquids, spectroscopy, medicinal chemistry, and synthetic developments. With a multicultural background and fluency in multiple languages, she has built a global research profile, contributing significantly to sustainability and pharmaceutical sciences. Currently serving as a Research Scientist at CSIRO in Australia, she leads and supports projects focused on sustainable carbon technologies and carbon capture efficiency. Her earlier career included leadership as a CERC Fellow at CSIRO, lecturer roles at the University of Newcastle and University of Sydney, and postdoctoral research at the University of Oxford and University College London. She has published extensively in high-impact journals, authored book chapters, and holds patents in hydrogen production and drug development. Her academic and industrial collaborations highlight her interdisciplinary approach, bridging fundamental research with applied solutions to address pressing global challenges in energy, health, and sustainability.

Profile

Google scholar

ORCID

Education

Dr. Michela Simone earned her Doctor of Philosophy from the University of Oxford, where she conducted pioneering research on branched sugar lactones under the mentorship of Professor George W. J. Fleet at the Dyson Perrins Laboratory and Chemistry Research Laboratory. Prior to this, she completed her Master of Science with first-class honours at the Victoria University of Manchester, focusing on the synthesis of muscarinic receptor agonists under Professor E. James Thomas. During her studies, she was awarded a European Union Socrates Award for an exchange program at the Georg-August University of Göttingen in Germany, where she worked on chemical and biological syntheses of pyripyropenes under Professor Uwe Beifuss. This international academic training provided her with a strong foundation in synthetic organic chemistry, carbohydrate chemistry, and medicinal chemistry. Her educational journey laid the groundwork for her later achievements in spectroscopy, drug discovery, and renewable energy research, demonstrating her ability to bridge chemistry with interdisciplinary applications.

Experience

Dr. Michela Simone’s professional journey reflects a balance of academic scholarship, research innovation, and industrial collaboration. Currently, she works at CSIRO as a Research Scientist in the Sustainable Carbon Technologies Group, where she applies her mechanistic and spectroscopic expertise to optimize carbon capture processes for industrial applications. Previously, as a CERC Fellow at CSIRO, she led a major project on sustainable hydrogen production, integrating physical chemistry, engineering, and physics, resulting in a patent for water-splitting processes. Her academic career includes tenure as a Lecturer in Medicinal Chemistry and Chemical Biology at the University of Newcastle, where she managed a 40:40:20 workload across research, teaching, and service while supervising her research group in glycobiology and synthetic chemistry. Earlier, she was a Lecturer in Chemistry at the University of Sydney, focusing on medicinal and biological chemistry. Her postdoctoral work at Oxford and University College London contributed to advances in protein interactions and medicinal chemistry.

Awards and Honors

Dr. Michela Simone’s career has been marked by recognition for her contributions to chemistry and interdisciplinary research. She has authored more than sixty-five peer-reviewed publications, invited book chapters, and holds patents in hydrogen production technologies and drug delivery systems, reflecting her innovative impact on both energy and healthcare. Her invited contributions to special issues in journals such as Molecules, Pharmaceuticals, and the European Journal of Medicinal Chemistry highlight her status as a recognized expert in boron chemistry, glycobiology, and green synthetic methods. She has been invited to contribute book chapters with leading publishers including Taylor & Francis, underscoring her international reputation. Her work has been spotlighted in editorial features such as “Women in Bioorganic Chemistry,” reflecting her role as a leader and role model in science. With a growing citation record, high h-index, and strong collaborations across academia and industry, she continues to be acknowledged for her research excellence and scientific leadership.

Research Focus

Dr. Michela Simone’s research focus lies at the intersection of green chemistry, renewable energy, and medicinal chemistry, with an emphasis on practical applications that address urgent global challenges. She has pioneered work in renewable fuels, including hydrogen generation, biomass conversion, carbon capture and storage, and redox flow batteries, aiming to reduce environmental impact while improving energy efficiency. Her work in carbohydrate chemistry and glycobiology has contributed to the development of high and low Fsp3 drug leads, with innovative approaches incorporating organic boron as a novel pharmacophore for medicinal chemistry and cancer therapies. She has also advanced the field of ionic liquids, exploring their potential in sustainable synthesis and material applications. Utilizing spectroscopy and mechanistic insights, she combines fundamental chemical principles with applied solutions, leading to patents and industrial collaborations. Her interdisciplinary approach integrates chemistry, physics, and engineering, establishing her as a global leader in research that bridges sustainability, energy innovation, and health.

 

Publications

 

Title: Endothelial C-type natriuretic peptide maintains vascular homeostasis
Year: 2014
Citation: 187

Title: The expanding utility of continuous flow hydrogenation
Year: 2015
Citation: 144

Title: Synchrotron based NEXAFS study on nitrogen doped hydrothermal carbon: Insights into surface functionalities and formation mechanisms
Year: 2017
Citation: 126

Title: A compendium of sugar amino acids (SAA): scaffolds, peptide-and glyco-mimetics
Year: 2007
Citation: 121

Title: Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis
Year: 2016
Citation: 111

Title: A compendium of cyclic sugar amino acids and their carbocyclic and heterocyclic nitrogen analogues
Year: 2013
Citation: 103

Title: Kiliani on ketoses: branched carbohydrate building blocks from D-fructose and L-sorbose
Year: 2004
Citation: 87

Title: Kiliani reactions on ketoses: branched carbohydrate building blocks from D-tagatose and D-psicose
Year: 2005
Citation: 79

Title: o-Vanillin Derived Schiff Bases and Their Organotin(IV) Compounds: Synthesis, Structural Characterisation, In-Silico Studies and Cytotoxicity
Year: 2019
Citation: 52

Conclusion

Dr. Michela Simone is an accomplished scientist whose interdisciplinary expertise in green chemistry, renewable energy, carbohydrate chemistry, and medicinal chemistry has led to impactful research, patents, and collaborations that advance sustainability and healthcare innovation worldwide.

Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi | Radiation oncology | Best Researcher Award

Dr. Parisa Shamsesfandabadi 🇺🇸 is a passionate radiation oncologist with a dynamic academic and clinical background, currently serving as Chief Resident at Allegheny Health Network in Pittsburgh, PA 💼. She combines a global medical foundation from Iran with extensive U.S. clinical training 🇮🇷➡️🇺🇸. Driven by innovation and compassion, Parisa has earned national recognition with multiple prestigious awards 🏅. Her dedication extends beyond clinical excellence to impactful research, global health, and mentorship 🌍📚. With hands-on experiences at leading institutions like Duke, UNC, and VA Medical Center, her expertise spans brain, breast, liver, and prostate cancer research 🧠💪. Parisa’s unique blend of research, service, and leadership reflects her lifelong commitment to patient care, academic excellence, and transformative cancer therapy 🌟. In addition to her clinical role, she actively contributes as an editorial assistant, social ambassador, and peer-reviewer to renowned medical journals and organizations 📖🤝. She’s a true rising star in oncology 🚀.

Profile

Education 🎓

📍 Chief Resident, Radiation Oncology – Allegheny Health Network, PA (2024–Present) 👩‍⚕️
📍 Residency, Radiation Oncology – Allegheny Health Network, PA (2019–2024) 💉
📍 Internship (PGY-1), Transitional Year – Southern Hills Hospital, Las Vegas, NV (2019–2020) 🏥
📍 M.D. – Kashan University of Medical Sciences, Iran (2007–2014) 🎓🇮🇷
📍 High School – Tehran Farzanegan School, NODET (2000–2007) 🧠🏫
Parisa’s academic journey reflects brilliance from the start, attending Iran’s elite NODET school 🌟. She pursued medicine at KaUMS, consistently ranking top in medical Olympiads 🥇. Her U.S. medical training includes internship and residency in highly reputed institutions, leading to her current leadership as Chief Resident 🧑‍⚕️. Her academic record is peppered with awards, research, and international training, preparing her for a successful future as a physician-scientist and leader in cancer care 🧬🩺.

Experience 👨‍🏫

📍 Chief Resident, Radiation Oncology – AHN (2024–Present)
📍 Research Associate – VA Medical Center, Durham, NC 🧪
📍 Visiting Scholar – Duke, UNC, CCC Las Vegas 🏫
📍 Research Visitor – RAI Lab, Duke University (Glioma Imaging) 🧠
📍 Research Associate – KaUMS, Iran (Probiotics Study) 🧃
📍 Medical Assistant – Advanced Pain Management, NV 💊
📍 Volunteer – Rural Clinics, Pediatrics & Geriatrics Programs 🧒👵
📍 Editorial Assistant – eContour 📘
📍 Communications Intern – RTOG Foundation 💬
Dr. Parisa brings a rich portfolio of clinical and research experience across top U.S. and international institutions 🌍. From clinical research on prostate and brain cancers to hands-on patient care and administrative duties, she is known for her leadership, empathy, and academic dedication 🏥🧠📊.

Awards & Recognitions 🏅

🎖 2024 RTOG Communications Intern
💰 2023 $25K Grant – MRLinac Sarcoma (Benedum Foundation)
🧳 2023 Travel Grants – ARS, ACRO, ACR
🥇 2022 Resident Best Abstract – ABS
🎖 2022 Editorial/Fellow Roles – eContour, The Mednet, NRG
🌟 2022 RePRT Peer Reviewer – Red Journal
🏆 2022 Travel Award – eContour Vulvar Cancer Guidelines
👩‍🎓 Olympiad Champion – 4x Gold in Iran Medical Olympiads
🧠 UNESCO Youth Award – Earthquake Awareness Project
🏅 Sharif University Medal – Math & Graphs Competition
🧪 Ranked 1st in Nationwide Chemistry Lab Exam
📕 Published Short Book – “World of Animals”
📚 Parisa’s excellence is recognized through national and international grants, editorial roles, peer-review selections, and top medical student honors 🏅. From early academic brilliance to clinical and research impact, her accolades reflect a rare blend of intellect, service, and innovation 🌍✨.

Research Interests 🔬

🧠 Radiogenomics – Brain Cancer Imaging (Duke, UNC)
🧬 MR-Linac SBRT – Liver, Pancreatic, Prostate, and Breast Cancers
💪 Strength Training Impact – Radiotherapy in Breast Cancer
🧲 Adaptive Radiation Therapy – CBCT, MRI-based Comparisons
🔍 Treatment Planning – Monte Carlo vs Cone Algorithm
🧫 Biomarker Evaluation – Breast Cancer (KaUMS & Leiden University)
🧃 Probiotics vs Regular Yogurt in Pediatric Diarrhea
🖥 Editorial & Peer Review Roles – Red Journal, The Mednet, eContour
Dr. Shamsesfandabadi’s research bridges advanced imaging, functional planning, and personalized therapy in oncology 🧠. Her projects focus on enhancing precision radiation therapy using radiogenomics, AI-driven adaptive planning, and improving survivorship through integrative approaches 💻💡. She’s driven to optimize outcomes in patients with complex cancers like gliomas, HCC, and pancreatic malignancies, while actively contributing to guidelines and clinical trials 🧪💥. A rising voice in the next-gen of physician-scientists 🌟.

Publications 
  • -Kirichenko, A., Uemura, T., Hasan, S., Lian, Y., Abel, S., Renz, P.,
    Shamsesfandabadi, P., Carpenter, J., Thai, N., “Stereotactic Body Radiotherapy
    (SBRT) for Hepatocellular Carcinoma (HCC) with Single Photon Emission
    Computed Tomography (SPECT) Functional Treatment Planning in Patients with
    Advanced Hepatic Cirrhosis.” Advances in Radiation Oncology (Accepted,
    July 2023).
  • Goss, M., Champ, C., Trombetta, M, Shamsesfandabadi, P., DeMartino, V.,
    Wegner, R., Beriwal, S., Eisen, V. “The Comparison of Collapsed Cone and
    Monte Carlo Algorithms in Tangential Breast Planning.” Journal of Radiotherapy
    in Practice. (April 2023).
  • Mazurowski, M.A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    “Radiogenomics of lower-grade glioma: algorithmically assessed tumor shape
    is associated with tumor genomic subtypes in a multi-institutional study with
    The Cancer Genome Atlas data.” Journal of Neuro-Oncology. 2017, May;
    133(1): 27-35. Cited in PubMed; PMID: 28470431.
  • Mazurowski, M. A., Clark, K., Czarnek, N. M., Shamsesfandabadi, P., et al.
    (2017, March 21). “Radiogenomic analysis of lower grade glioma: a pilot multiinstitutional study shows an association between quantitative image features
    and tumor genomics.” SPIE, The international society for optics and photonics.
  • – Sharif, A., Kheirkhah, D., Shamsesfandabadi, P., et al. “Comparison of Regular
    and Probiotic Yogurts in Treatment of Acute Watery Diarrhea in Children.”
    Journal of Probiotics and Health. 2016, Feb; 5(1): 164.

Manijeh Beigi | Medical Physics | Best Researcher Award

Dr. Manijeh Beigi | Medical Physics | Best Researcher Award

Dr. Manijeh Beigi is an Assistant Professor in the Radiation Oncology Department at Iran University of Medical Sciences. She specializes in dosimetry, radiotherapy treatment planning, and quality audits, with a focus on using machine learning for radiomics and dosiomics analysis. Dr. Beigi earned her Ph.D. in Medical Physics from Tehran University of Medical Sciences in 2018, where she researched the application of Diffusion Tensor Imaging (DTI) in radiotherapy planning. With over a decade of experience in radiotherapy physics, she has worked in multiple hospitals, including Imam Hosein, Haft-e-Tir, and Pardis Niloo Cancer Center. She is actively involved in research on predicting radiotherapy toxicity and advanced MR imaging applications. Dr. Beigi has mentored numerous students, contributed to high-impact journals, and presented at international conferences. Her research aims to enhance radiotherapy precision and patient safety through cutting-edge imaging and AI-driven models. 🎓🔬

Profile

Education 🎓

Dr. Manijeh Beigi holds a Ph.D. in Medical Physics (2018) from Tehran University of Medical Sciences, where she developed automated clinical target volume determination for glioma treatment using multiparametric MRI. She completed her M.Sc. in Medical Physics (2010) at Tarbiat Modares University, focusing on radiotherapy dosimetry and quality audits in Varian linear accelerators. Her coursework covered key topics such as radiotherapy physics, radiobiology, MRI, CT, and PET physics, statistical methods, and treatment planning. Throughout her academic journey, she has specialized in advanced imaging techniques, radiomics, and AI-based predictive modeling for radiotherapy applications. Dr. Beigi’s education has provided her with strong expertise in medical physics, treatment planning optimization, and quality assurance, positioning her as a leader in radiation oncology research and innovation. 📚

Experience 👨‍🏫

Dr. Manijeh Beigi has been an Assistant Professor at Iran University of Medical Sciences since 2020, where she focuses on radiotherapy physics, treatment planning, and quality assurance. Previously, she worked as a Radiotherapy Physicist at Imam Hosein Hospital (2010-2016), Haft-e-Tir Hospital (2016-Present), and Pardis Niloo Cancer Center (2019-2021), specializing in 3D conformal radiotherapy, IMRT planning, machine QA, and dosimetry. She was also a Research Assistant (2012-2018) at Tehran University of Medical Sciences, collaborating on quantitative MRI and spectroscopy research. Dr. Beigi has significant experience in mentoring students, managing research projects, and implementing AI-driven radiotherapy solutions. Her work integrates imaging and machine learning to optimize treatment efficacy and minimize patient toxicity. 💼🔬

Research Interests 🔬

Dr. Manijeh Beigi’s research centers on dosimetry, radiotherapy quality audits, and the application of machine learning in radiomics and dosiomics. She explores AI-driven models to predict radiotherapy toxicity and optimize treatment planning. Her work integrates advanced MRI techniques, such as Diffusion Tensor Imaging (DTI), to enhance clinical target volume delineation for gliomas and other cancers. She investigates imaging biomarkers to assess radiation-induced damage and improve treatment precision. Additionally, Dr. Beigi is actively involved in multi-disciplinary research collaborations, utilizing deep learning for medical image analysis. Her contributions aim to advance radiation oncology by improving accuracy, reducing side effects, and personalizing treatment plans. 🧬📡

Dr. Manijeh Beigi has received several accolades for her contributions to medical physics and radiotherapy research. She has been recognized for her work in AI-driven radiomics and dosiomics at international conferences, including ESTRO and AAPM. Her research on glioma segmentation using DTI and radiotherapy toxicity prediction has been published in top-tier journals. She has also been awarded grants for her studies on advanced MRI applications in radiotherapy planning. Additionally, Dr. Beigi has played a key role in multi-institutional research collaborations, earning recognition for her leadership in medical imaging and quality assurance. 🏆🎖️

Publications 📚

Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi | Radiation oncology | Best Researcher Award

Dr. Pedram Fadavi, M.D., is a distinguished radiation oncologist and associate professor at Iran University of Medical Sciences (IUMS). Born in Tehran, Iran (1974), he specializes in cancer treatment, radiotherapy, and oncological research. With over two decades of experience, he has contributed extensively to academia and clinical practice. His expertise spans breast, head, neck, and gynecologic cancers. He has published influential research in radiomics, chemotherapy delays, and treatment-induced complications. A dedicated educator, he mentors medical students and residents while advancing oncology research. 📚💡

Profile

Education 🎓

Dr. Fadavi earned his M.D. (2000) and board certification in Radiation Oncology (2006) from Shahid Beheshti University, Tehran. He completed a seven-year medical program (1993-2000) and specialized in radiation oncology during his residency (2002-2006). He holds an Iran Medical Council license (No. 76602) and actively contributes to medical education and research at IUMS. His training provided a strong foundation in oncologic treatments and innovative radiotherapy techniques. 🔬📖

Experience 👨‍🏫

Since 2006, Dr. Fadavi has served as a radiation oncologist at Haftome Tir Hospital (IUMS). He became an associate professor in 2008, teaching at IUMS and Tehran University of Medical Sciences (2011-2013). His clinical expertise includes radiotherapy advancements, cancer management, and interdisciplinary oncology research. He has led multiple projects addressing radiation-induced complications and patient outcomes. His leadership in academic and clinical oncology has shaped the future of radiation therapy in Iran. 🌍🔬

Research Interests 🔬

Dr. Fadavi’s research centers on radiomics, predictive modeling, and improving radiotherapy outcomes. His recent studies explore machine learning applications in radiation toxicity prediction, chemotherapy delays, and novel treatment strategies for breast, cervical, and head-and-neck cancers. He investigates biomarkers for cancer prognosis and response to therapy, with a strong emphasis on precision oncology. His work in computational oncology and artificial intelligence-driven diagnostics is shaping the future of personalized cancer treatment. 💻🧬Awards & Recognitions 🏅

Dr. Fadavi has received numerous accolades for his contributions to radiation oncology and medical research. His work on radiomics, treatment toxicity, and innovative oncological therapies has been recognized in national and international forums. His publications in leading journals and collaborations with top researchers underscore his impact on global cancer research. He has also been honored for his excellence in medical education, research innovation, and commitment to improving patient care. 📜🏅

Publications 📚